Source: International Congress 2016 – The future of tyrosin kinase inhibitors



Rating:

Share or cite this content

Citations should be made in the following way:
Rafael Rosell (Barcelona, Spain). Understanding the mechanisms of TKIs: the cycle of inhibition and resistance. International Congress 2016 – The future of tyrosin kinase inhibitors

Member's Comments

No comment yet.

Related content which might interest you: EGFR-inhibition: resistance mechanisms and new strategies Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance. Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 When and how to identify resistance mechanisms to targeted therapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 TRAP1 downregulation could overcome gefitinib resistance in NSCLC via EMT reversal Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018 Targeting the mTOR signaling pathway to inhibit lung cell senescence in COPD Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs? Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019 Activation of proteolytic mechanisms in response to inflammatory stimuli: a possible role in the development of the aleolocapillary barrier damage Source: Eur Respir J 2003; 22: Suppl. 45, 458s Year: 2003 Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001 Modified sensitivity of alveolar cells to TRAIL-mediated apoptosis: a mechanism involved in emphysema pathogenesis with a potential impact on cancer therapy research Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury Year: 2009 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010